Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery

•Thermosensitive liposomes are being developed for cancer.•LTLD is the first liposomal drug carrier entering human trials.•Early clinical data of LTLD has demonstrated feasibility, safety and activity.•Thermosensitive liposomes are a delivery platform to treat solid tumors.